Contrasting Shiseido (OTCMKTS:SSDOY) and Trillium Therapeutics (NASDAQ:TRIL)

Share on StockTwits

Shiseido (OTCMKTS:SSDOY) and Trillium Therapeutics (NASDAQ:TRIL) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for Shiseido and Trillium Therapeutics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Shiseido 2 2 2 0 2.00
Trillium Therapeutics 0 1 6 0 2.86

Trillium Therapeutics has a consensus target price of $21.83, suggesting a potential upside of 137.06%.

Earnings & Valuation

This table compares Shiseido and Trillium Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Shiseido $10.38 billion 0.00 $676.77 million $1.72 N/A
Trillium Therapeutics $120,000.00 7,906.86 -$41.62 million ($1.38) -6.67

Shiseido has higher revenue and earnings than Trillium Therapeutics. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Shiseido, indicating that it is currently the more affordable of the two stocks.


This table compares Shiseido and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Shiseido -1.33% 0.95% 0.40%
Trillium Therapeutics N/A -70.00% -28.84%

Risk & Volatility

Shiseido has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of Shiseido shares are owned by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.


Trillium Therapeutics beats Shiseido on 6 of the 11 factors compared between the two stocks.

Shiseido Company Profile

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; skincare products, shampoo, and other haircare products, as well as body care products; and hair care and styling products, as well as hair color and perm solutions for hair salons. It also conducts restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. It sells its products through department stores, specialty stores, drug stores, and general merchandising stores. The company was founded in 1872 and is headquartered in Tokyo, Japan.

Trillium Therapeutics Company Profile

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for Shiseido Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shiseido and related companies with's FREE daily email newsletter.